Artelo Biosciences, Inc.

ARTLNASDAQ · Healthcare · Biotechnology

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid syste…

$2.07-1.43%

报价 2026-11-13

市值

$7.2M

$-1.3M

PE (TTM)

–

预期 PE (FY2026)

–

52 周区间距高点 -97.8%

$1.91$94.86

筛选结果

pipeline · 2026-11-13

Filter✗ 高增长✗ Cheap✗ GARP

excluded industry: Biotechnology

研究结论

还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16

公司	市值	今日	预期营收增速	毛利率	PE	EV/EBITDA	P/FCF
ARTLArtelo Biosciences, Inc.	$7.2M	-1.4%	–	0%	–	–	–
GTBPGT Biopharma, Inc.	$4.7M	-3.0%	-28.1%	0%	–	–	–
REVBRevelation Biosciences, Inc.	$2.4M	-2.6%	–	0%	–	–	–
SPRCSciSparc Ltd.	$205,142	-0.6%	–	64.5%	–	–	–
SLXNSilexion Therapeutics Ltd.	$52,296	-25.6%	–	0%	–	–	–
同行中位数	–	–	-28.1%	0%	–	–	–

研究全文

L2 基本面 memo

尚无基本面 memo

点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

暂无季度数据（首次研究运行后填充）。

研究材料

Filing 摘要

8-K · 2026-05-150001640334-26-000903 10-Q · 2026-05-140001640334-26-000869 S-1 · 2026-04-070001640334-26-000670 8-K · 2026-04-070001640334-26-000662 8-K · 2026-03-300001640334-26-000574 S-1/A · 2026-03-240001640334-26-000540 S-1 · 2026-03-240001640334-26-000543 S-1/A · 2026-03-230001640334-26-000515

电话会纪要摘要

暂无纪要摘要。

我的笔记

AI 刷新不会修改

判断与复查· 可选：填复查日期后会进首页待办

加载中…

关键指标

其他估值

EV/EBITDA–

P/FCF–

P/S–

MC/GP–

PB0.44x

PEG0.00x

经营

营收 (TTM)$0

营收同比 (TTM)–

净利润 (TTM)$-11.3M

净利同比 (TTM)–

下一财年营收增速–

毛利率0%

经营利润率0%

净利率0%

FCF (TTM)$-11.8M

ROE-519.1%

ROIC-219.4%

资产负债

负债/权益0.01

流动比率3

Beta0.05

财务数据更新于 2026-09-23

分析师

EPS 超预期近 8 季 2 次 beat

+5.5

+55.8

-168

-440

-33.9

-384

-41.4

-413

2024-082026-05

内部人交易

近 180 天 · 仅公开市场买卖

无公开市场买入或卖出。

公司资料

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

展开全文

CEO Gregory D. Gorgas

员工 6

IPO 2019-06-21

官网 StockAnalysis

数据截至 2026-09-23